Skip to main content
. 2021 Oct 30;13(21):5459. doi: 10.3390/cancers13215459

Figure 7.

Figure 7

18F-FDG and 89Zr-trastuzumab PET scans of a patient with a 89Zr-trastuzumab PET scan considered HER2-positive breast cancer (up) and a 89Zr-trastuzumab PET scan considered HER2 negative (bottom) [15].